Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Authors

E L Mayer, Dana-Farber Cancer Institute
C Ma, Washington University School of Medicine in St. Louis
et al.

Journal

Annals of Oncology

Publication Date

2-1-2026

Volume

37

Issue

2

First Page

180

Last Page

193

Document Type

Open Access Publication

DOI

10.1016/j.annonc.2025.10.006

Rights and Permissions

Mayer EL, Bidard FC, Park YH, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching PA, Nowecki Z, Chen SC, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn JH, Zhu Y, Leddin I, Miralles MS, Bartlett CH, Turner N. Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy. Ann Oncol. 2026 Feb;37(2):180-193. doi: 10.1016/j.annonc.2025.10.006. © 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Recommended Citation

Mayer, E L; Ma, C; and et al., "Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy." Annals of Oncology. 37, 2. 180 - 193. (2026).
https://digitalcommons.wustl.edu/oa_4/6437

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.